What outstanding news! This PR indicates Brilacidin will not only be tested at a second RBL lab but will focus on the immune effects of Brilacidin versus Covid 19.
"Scientists at the Public Health Research Institute plan to evaluate Brilacidin’s inhibitory effect on SARS-CoV-2 viral replication in primary immune mediators (peripheral blood mononuclear cells, T cells, B cells, monocytes, macrophages) obtained from both young and old donors to assess age-dependent host responses to the novel coronavirus. Brilacidin drug substance has been received by the Institute and is now available for testing."
Good luck to all,Farrell
News 
Market Data 
Discover 
